SARS-CoV-2 antibody response duration and neutralization following natural infection.
COVID-19
Neutralizing antibodies
SARS-CoV-2
Serosurvey
Journal
Journal of clinical virology plus
ISSN: 2667-0380
Titre abrégé: J Clin Virol Plus
Pays: England
ID NLM: 9918283581506676
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
1
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
The role of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) neutralizing antibody response from natural infection and vaccination, and the potential determinants of this response are poorly understood. Characterizing this antibody response and the factors associated with neutralization can help inform future prevention efforts and improve clinical outcomes in those infected. The goals of this study were to prospectively evaluate SARS-CoV-2 antibody levels and the neutralizing antibody responses among naturally infected adults and to determine demographic and behavioral factors independently associated with these responses. Serum was collected from seropositive individuals at baseline, four-weeks, and three-months following their first study visit to be evaluated for antibody levels. Detection of neutralizing antibodies was performed at baseline. Participant demographic and behavioral information was collected via web questionnaire prior to their first visit. At baseline, higher antibody levels were associated with better neutralization capacity, with 83% of participants having detectable neutralizing antibodies. We found an age-dependent effect on antibody level and neutralization capacity with participants over 65 years having significantly higher levels. Ethnicity, heart disease, autoimmune disease, and COVID symptoms were associated with higher antibody levels, but not with increased neutralization capacity. Work environment during the pandemic correlated with increased neutralization capacity, while kidney or liver disease and traveling out of state after February 2020 correlated with decreased neutralization capacity, however neither correlated with antibody levels. Our data show that natural infection by SARS-CoV-2 can induce a humoral response reflected by high antibody levels and neutralization capacity.
Sections du résumé
Background
UNASSIGNED
The role of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) neutralizing antibody response from natural infection and vaccination, and the potential determinants of this response are poorly understood. Characterizing this antibody response and the factors associated with neutralization can help inform future prevention efforts and improve clinical outcomes in those infected.
Objectives
UNASSIGNED
The goals of this study were to prospectively evaluate SARS-CoV-2 antibody levels and the neutralizing antibody responses among naturally infected adults and to determine demographic and behavioral factors independently associated with these responses.
Methods
UNASSIGNED
Serum was collected from seropositive individuals at baseline, four-weeks, and three-months following their first study visit to be evaluated for antibody levels. Detection of neutralizing antibodies was performed at baseline. Participant demographic and behavioral information was collected via web questionnaire prior to their first visit.
Results
UNASSIGNED
At baseline, higher antibody levels were associated with better neutralization capacity, with 83% of participants having detectable neutralizing antibodies. We found an age-dependent effect on antibody level and neutralization capacity with participants over 65 years having significantly higher levels. Ethnicity, heart disease, autoimmune disease, and COVID symptoms were associated with higher antibody levels, but not with increased neutralization capacity. Work environment during the pandemic correlated with increased neutralization capacity, while kidney or liver disease and traveling out of state after February 2020 correlated with decreased neutralization capacity, however neither correlated with antibody levels.
Conclusions
UNASSIGNED
Our data show that natural infection by SARS-CoV-2 can induce a humoral response reflected by high antibody levels and neutralization capacity.
Identifiants
pubmed: 37654784
doi: 10.1016/j.jcvp.2023.100158
pmc: PMC10470471
mid: NIHMS1926189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Emerg Microbes Infect. 2020 Dec;9(1):2105-2113
pubmed: 32893735
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Sci Immunol. 2020 Jul 3;5(49):
pubmed: 32620559
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Front Immunol. 2021 Jun 16;12:708523
pubmed: 34220870
Nat Commun. 2017 Mar 16;8:14722
pubmed: 28300075
Emerg Infect Dis. 2022 Mar;28(3):556-563
pubmed: 35081021
BMC Infect Dis. 2022 Jul 13;22(1):610
pubmed: 35831798
JAMA Oncol. 2022 May 1;8(5):748-754
pubmed: 35266953
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Front Immunol. 2022 Jan 31;13:830710
pubmed: 35173741
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Viruses. 2021 Apr 28;13(5):
pubmed: 33925055
Nature. 2022 Feb;602(7898):560
pubmed: 35145295